HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community’s infections

AIDS Reviews

Volumn 19, Issue 3, 2017, Pages 134-147

  Spaulding, Anne C ^a,b   Anderson, Emeli J ^a   Khan, Mohammed A ^a   Taborda Vidarte, Cesar A ^b   Phillips, Jennifer A ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Epidemiology; HCV. HIV. Prison; Injection drug use; Jail; Prevention

Indexed keywords

BOCEPREVIR; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OPIATE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT;

ANTIRETROVIRAL THERAPY; ARTICLE; COMMUNITY ACQUIRED INFECTION; DISEASE BURDEN; DRUG USE; EPIDEMIC; GENDER; HEALTH CARE COST; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ELISA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LAW ENFORCEMENT; MEN WHO HAVE SEX WITH MEN; NEEDLE SHARING; PRE-EXPOSURE PROPHYLAXIS; PRISON NURSING; PRISONER; SEROPREVALENCE; TRANSACTIONAL SEX; VIRAL LOAD TESTING; VIRUS TRANSMISSION; DISEASE TRANSMISSION; HEALTH CARE POLICY; MASS SCREENING; PREVALENCE; PRISON; TRANSMISSION; UNITED STATES;

ANTIVIRAL AGENTS; DISEASE TRANSMISSION, INFECTIOUS; HEALTH POLICY; HEPATITIS C; HIV INFECTIONS; HUMANS; MASS SCREENING; PREVALENCE; PRISONS; UNITED STATES;

EID: 85028851762     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: 10.24875/AIDSRev.M17000006     Document Type: Article

References (100)

1. Carson EA, Anderson E. Prisoners in 2015. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. NCJ 250229. Available at: https://www.bjs.gov/index.cfm?ty=pbdetail&iid=5869 [Accessed January 20, 2017].
2. Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano D. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am J Epidemiol. 2003;158:695-704.
3. Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203:1215-21.
4. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300.
5. Centers for Disease Control and Prevention. HIV Surveillance Report, 2015; vol. 27 Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Published November 2016. [Accessed January 20, 2017].
6. World Prison Brief, webpage of the International Centre for Prison Studies, Kings College London, University of London. Available at: http://www.prisonstudies.org/info/worldbrief/[Accessed January 4, 2017].
7. Kaeble D, Glaze L. Correctional Populations in the United States, 2015. Bureau of Justice Statistics. NCJ 250374. Available at: https://www.bjs. gov/content/pub/pdf/cpus15.pdf. [Accessed January 7, 2017].
8. Minton TD, Zeng Z. Jail inmates mid-year 2015. Washington, DC: US Department of Justice, Office of Justice Programs, Bureau of Justice Statistics. NCJ 50394 Available at: https://www.bjs.gov/content/pub/pdf/ji15.pdf [Accessed February 20, 2017].
9. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of, and releasees from, US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;11:e7558.
10. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090-101.
11. Varan A, Mercer D, Stein M, Spaulding A. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Pub Health Rep. 2014;129:187-95.
12. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353-63.
13. Easterbrook P, Johnson C, Figueroa C, Baggaley R. HIV and hepatitis testing: Global progress, challenges, and future directions. AIDS Rev. 2016;18:3-14.
14. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35:305-12.
15. Hanrahan JP, Wormser GP, Maguire GP, DeLorenzo LJ, Gavis G. Opportunistic infections in prisoners. N Engl J Med. 1982;1982:498.
16. Hammett T. Acquired immunodeficiency syndrome in correctional facilities: a report of the National Institute of Justice and the American Correctional Association. Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep. 1986;35:195-9.
17. Estelle v. Gamble 1976. 429 US 97, 97 S Ct 285, 50 L Ed 2d 251.
18. Brien PM, Harlow CW. HIV in prisons, 1993. Bureau of Justice Statistics, 8/95 NCJ 152765. Available at: http://www.ojp.usdoj.gov/bjs/pub/pdf/hivp93.pdf [Accessed July 2, 2010].
19. Maruschak LM. HIV in prisons, 2002-10. Bulletin of the Bureau of Justice Statistics. September 2012, NCJ 238877. Available at: http://www.bjs.gov/content/pub/pdf/hivp10.pdf. [Accessed April 14, 2014].
20. Jacques B, Michael JB, Stephanie Z, Hal BJ, Charles TL. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31:1476-81.
21. Maruschak LM, Berzofsky M, Unangs J. Medical Problems of State and Federal Prisoners and Jail Inmates, 2011-12. NCJ 248491. Available at: http://www.bjs.gov/content/pub/pdf/mpsfpji1112.pdf [Accessed April 24, 2015].
22. Centers for Disease Control and Prevention. HIV Surveillance Report, 2013; vol. 25. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Published November 2014. [Accessed January 23, 2017].
23. Centers for Disease Control and Prevention. HIV Testing Implementation Guidance for Correctional Settings. Available at: http://www.cdc.gov/hiv/topics/testing/resources/guidelines/correctional-settings/index.htm. 2008: 1-38.
24. Rumble C, Pevalin DJ, O’Moore É. Routine testing for blood-borne viruses in prisons: a systematic review. Eur J Pub Health. 2015;25: 1078-88.
25. Strick LB, MacGowan RJ, Margolis A, Belcher L. HIV Screening of male inmates during prison intake medical evaluation-Washington, 2006-2010 (Reprinted from MMWR. 2011;60:811-13. 2011). Amer Medical Assoc, Chicago. 2011:1756-7.
26. Spaulding AC, Kim MJ, Corpening KT, Carpenter T, Watlington P, Bowden CJ. Establishing an HIV Screening Program Led by Staff Nurses in a County Jail. J Public Health Manag Practice 2015;21:538-45.
27. Kavasery R, Maru DSR, Sylla LN, Smith D, Altice FL. A prospective controlled trial of routine opt-out HIV testing in a men’s jail. PLoS One 2009;4:e8056.
28. Kavasery R, Maru DSR, Cornman-Homonoff J, Sylla LN, Smith D, Altice FL. Routine opt-out HIV testing strategies in a female jail setting: A prospective controlled trial. PLoS One. 2009;4:e7648.
29. Centers for Disease Control and Prevention (CDC). Routine voluntary opt-out HIV screening into medical intake, Fulton County Georgia, 2011-2012. MMWR Morb Mortal Wkly Rep. 2013;62:495-7.
30. Spaulding AC, Kim MJ, Corpening K, Carpenter T, Watlington P, Bowden CJ. Establishing an HIV screening program led by staff nurses in a county jail. J Public Health Manag Pract. 2015;21:538-45.
31. Iroh PA, Mayo H, Nijhawan AE. The HIV care cascade before, during, and after incarceration: a systematic review and data synthesis. Am J Public Health. 2015;105:e5-16.
32. Spaulding AC, Booker CA, Freeman SH, et al. Jails, HIV testing and linkage to care services: an overview of the EnhanceLink initiative. AIDS Behav. 2013;17(Suppl 2):S100-7.
33. Spaulding AC, Perez SD, Seals RM, Kavasery R, Hallman M, Weiss P. The diversity of release patterns for jail detainees: Implications for public health interventions. Am J Public Health. 2011;101:S347-52.
34. McLemore M. Paying the Price: Failure to Deliver HIV Services in Louisiana Parish Jails. Human Rights Watch. 2016. Available at: https://www. hrw.org/report/2016/03/29/paying-price/failure-deliver-hiv-services-louisiana-parish-jails. [Accessed January 4, 2017].
35. Desai AA, Latta ET, Spaulding A, Rich JD, Flanigan TP. The importance of routine HIV testing in the incarcerated population: the Rhode Island experience. AIDS Educ Prev. 2002;14:45-52.
36. Centers for Disease Control and Prevention (CDC). Routine jail-based HIV testing-Rhode Island, 2000--2007. MMWR Morb Mortal Wkly Rep. 2010;59:742-5.
37. Wohl DA, Golin C, Rosen DL, May JM, White BL. Detection of Undiagnosed HIV Among State Prison Entrants. JAMA. 2013;310:2198-9.
38. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
39. Macalino G, Vlahov D, Sanford S, et al. Prevalence and incidence of HIV, HBV, and HCV infections among males in RI prisons. Am J Public Health. 2004;94:1218-23.
40. Gough E, Kempf MC, Graham L, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health. 2010;10:777.
41. Rich JD, Dickinson BP, Macalino G, et al. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr. 1999;22:161-6.
42. Taussig J, Shouse RL, LaMarre M, et al. HIV transmission among male inmates in a state prison system--Georgia, 1992-2005. MMWR Morb Mortal Wkly Rep. 2006;55:421-6.
43. Krebs CP, Simmons M. Intraprison HIV transmission: an assessment of whether it occurs, how it occurs, and who is at risk. AIDS Educ Prev. 2002;14:53-64.
44. Steiner A. Implementing California’s Prisoners Protections for Family and Community Health Act: A Mandated Condom Access Program within State Prisons. 2016 National STD Prevention Conference; 2016: CDC.
45. McCuller WJ, Harawa NT. A condom distribution program in the Los Angeles Men’s Central Jail: Sheriff Deputies’ attitudes and opinions. J Correct Health Care. 2014;20:195-202.
46. Dolan K, Rutter S, Wodak AD. Prison-based syringe exchange programmes: a review of international research and development. Addiction. 2003;98:153-8.
47. Dolan K. Evidence about HIV transmission in prisons. Canadian HIVAIDS Policy Law Newsletter. 1997;3-4:32-8.
48. Eholié SP, Badje A, Kouame GM, et al. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Res Ther. 2016;13:27.
49. Hammett T. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health. 2006;96:974-8.
50. Mutter RC, Grimes RM, Labarthe D. Evidence of intraprison spread of HIV infection. Arch Intern Med. 1994;154:793-5.
51. Weinbaum C, Lyerla R, Margolis H. Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR Recomm Rep. 2003;52(RR-1):1-36.
52. Vescio MF, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008;62:305-13.
53. U.S. Public Health Service. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50:1-52.
54. Hammett T, Harmon M, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789-94.
55. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14.
56. Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep. 2011;60:537-41.
57. Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59:1411-9.
58. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged
59. Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016; 375:229-39.
60. Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73:323-31.
61. Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis c virus infections in the u.s. surveillance system: A case series and chart review. Ann Intern Med. 2015;163:254-61.
62. He T, Li K, Roberts MS, et al. Prevention of Hepatitis C by Screening and Treatment in US Prisons. Ann Intern Med. 2016;164:84-92.
63. Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania State prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health. 2014;106:e69-74.
64. Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C screening of the “Birth Cohort” (Born 1945-1965) and younger inmates of New York City jails. Am J Public Health. 2016;106:1276-7.
65. Kuncio DE, Newbern EC, Fernandez-Viña MH, Herdman B, Johnson CC, Viner KM. Comparison of risk-based hepatitis C Screening and the true seroprevalence in an urban prison system. J Urban Health. 2015;92:379-86.
66. Stockman LJ, Greer J, Holzmacher R, et al. Performance of risk-based and birth-cohort strategies for identifying hepatitis C Virus infection among people entering prison, Wisconsin, 2014. Public Health Rep. 2016;131:544-51.
67. Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307:1259-60.
68. Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California State Correctional System. Clin Infect Dis. 2005;41:177-86.
69. Beckman AL, Bilinski A, Boyko R, et al. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff. 2016;35:1893-901.
70. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J Public Health. 2016;38:130-7.
71. Beckwith CG, Kurth AE, Bazerman L, et al. Survey of US correctional institutions for routine HCV testing. Am J Public Health. 2015;105:68-71.
72. DeLaFlor C, Porsa E, Nijhawan AE. Opt-out HIV/HCV testing among jail inmates. CROI. February 13-16, 2017, Seattle, Washington. [Abstract # 957].
73. Cocoros N, Nettle E, Church D, et al. Screening for Hepatitis C as a Prevention Enhancement (SHAPE) for HIV: An Integration Pilot Initiative in a Massachusetts County Correctional Facility. Public Health Rep. 2014;129:5-11.
74. Spaulding A, Bowden C, Miller L, Mbaba M, Church J. (Invited Presentation). An IIDDEALL Program for Jails: Integrating Infectious Disease Detection at Entry and Linkage to Care. CDC HIV Prevention Conference. Atlanta GA, 2011.
75. Spaulding A, Kim A, Harzke A, et al. Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. Top Antivir Med. 2013;21:27-35.
76. Wenger PJ, Rottnek F, Parker T, Crippin JS. Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health. 2014;104:1722-7.
77. Schoenbachler BT, Smith BD, Sena AC, et al. Hepatitis C virus testing and linkage to care in North Carolina and South Carolina Jails, 2012-2014. Public Health Rep. 2016;131(Suppl 2):98-104.
78. Akiyama MJ, Kaba F, Rosner Z, et al. Correlates of hepatitis C virus infection in the Targeted Testing Program of the New York City Jail System. Public Health Rep. 2017;132:41-7.
79. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. Hepatology. 2013;58:1215-24.
80. Marco A, Gallego C, Caylà JA. Incidence of Hepatitis C Infection among Prisoners by Routine Laboratory Values during a 20-Year Period. PLoS One. 2014;9:e90560.
81. Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010;105:216-23.
82. Das M, Chu PL, Santos G-M, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
83. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-9.
84. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis. 2015;28:576-82.
85. Surveillance and Treatment of Prisoners With Hepatitis C. Available at: https://clinicaltrials.gov/ct2/show/NCT02064049.
86. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791-6.
87. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187-90.
88. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The costeffectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61:157-68.
89. Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15:827-37.
90. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406.
91. Aspinall EJ, Mitchell W, Schofield J, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016;23:1009-16.
92. Spaulding AC, Sharma A, Messina LC, Zlotorzynska M, Miller L, Binswanger IA. A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991. Am J Public Health. 2015:e1-7.
93. Martin NK, Vickerman P, Goldberg D, Hickman M. HCV treatment as prevention in prison: Key issues. Hepatology. 2015;61:402-3.
94. Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58:1598-609.
95. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55:49-57.
96. Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161:546-53.
97. He T, Li K, Roberts M, et al. Prevention of hepatitis C by screening and treatment in US prisons. Ann Intern Med. 2016;164:84.
98. Loftus P, Fields G. High cost of new hepatitis C drugs strains prison budgets, locks many out of care. Wall Street Journal. 2016. Available at: https://www.wsj.com/articles/high-cost-of-new-hepatitis-c-drugs-strainsprison-budgets-locks-many-out-of-cure-1473701644
99. Committee on Finance, United States Senate. The price of sovaldi and its impact on the U.S. health care system. December 2015. Available at: https://www.finance.senate.gov/download/the-price-of-sovaldi-and-its-impacton-the-us-health-care-system-full-report. [Accessed February 24, 2017].
100. Hedegaard H, Warner M, Minino AM. Drug overdose deaths in the United States, 1999-2015. NCHS data brief No. 273 February 2017. National Center for Health Statistics. 2017. Available at: https://www.cdc. gov/nchs/data/databriefs/db273.pdf [Accessed February 25, 2017].